The DOI matches its Crossref record.
Unusual lipid structures selectively reduce the toxicity of amphotericin B.
Open accessAbstract
Ribbon-like structures result when amphotericin B interacts with lipid in an aqueous environment. At high ratios of amphotericin to lipid these structures, which are lipid-stabilized amphotericin aggregates, become prevalent resulting in a dramatic attenuation of amphotericin-mediated mammalian cell, but not fungal cell, toxicity. Studies utilizing freeze-etch electron microscopy, differential scanning calorimetry, 31P NMR, x-ray diffraction, and optical spectroscopy revealed that this toxicity attenuation is related to the macromolecular structure of the complexes in a definable fashion. It is likely that amphotericin in this specific form will have a much improved therapeutic utility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Surfactant self-assembly objects as novel drug delivery vehicles
Drummond, C. J., & Fong, C. (1999) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00020-0 · Cited by 515
Semple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00343-6 · Cited by 454
Self-citationLiposomes in Drug Delivery: Clinical, Diagnostic and Ophthalmic Potential
Gregoriadis, G., & Florence, A. T. (1993) · Drugs · doi:10.2165/00003495-199345010-00003 · Cited by 452
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Wong-Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998) · Clinical Infectious Diseases · doi:10.1086/514704 · Cited by 395
Cavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 382
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Carrier effects on biological activity of amphotericin B
Brajtburg, J., & Bolard, J. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.512 · Cited by 310
Amphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado-Santiago, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 299
Fenske, D. B., & Cullis, P. R. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.25 · Cited by 253
Self-citationReview and analysis of FDA approved drugs using lipid-based formulations
Savla, R., Browne, J., Plassat, V., Wasan, K. M., & Wasan, E. K. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1342654 · Cited by 225
Walsh, T. J., Whitcomb, P., Piscitelli, S., Figg, W. D., Hill, S., Chanock, S. J., Jarosinski, P., Gupta, R., & Pizzo, P. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1944 · Cited by 109
Swenson, C. E., Perkins, W. R., Roberts, P., Ahmad, I., Stevens, R., Stevens, D. A., & Janoff, A. S. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.767 · Cited by 82
Self-citation
Metadata
- Authors
- Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., Taraschi, T., Gruner, S. M., Shyamsunder, E., & Tate, M. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1988-08
- Volume
- 85
- Issue
- 16
- Pages
- 6122-6126
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2129309504
- Cited by
- 223
- References
- 0
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.